Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05704088
Other study ID # MD.21.12.574
Secondary ID
Status Active, not recruiting
Phase Phase 4
First received
Last updated
Start date October 8, 2022
Est. completion date December 8, 2023

Study information

Verified date January 2023
Source Mansoura University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this Randomized, controlled trial in 100 patients with LN with an estimated glomerular filtration rate (eGFR) of 25-75 ml/min/1.73m2. Diagnosis of LN was performed by renal biopsy, and all of the renal biopsies were carried out at urology and nephrology center. 1. The main questions it aims to answer are: - Assess the role of sodium glucose co transporter 2 inhibitors (SGLT2i) in regression of ongoing kidney and cardiac diseases among diabetic or non-diabetic patients with lupus nephritis (LN) under different immunosuppressive therapies. - Investigate the impact of SGLT2i on bone and mineral metabolism in these patients. Participants will be randomized into two groups : - Study group: will receive SGLT2i as add on drug or replace another drug according to the patient clinical situation, Dapagliflozin 10 mg will be used once daily with or without food. - Control group: will be maintained on their medication.


Description:

Study sitting: Nephrology and renal transplant unit at urology and nephrology center in Mansoura University. Study design and sample size: Randomized, controlled trial that will include 100 patients with Lupus nephritis (LN) with an estimated glomerular filtration rate of 25-75 ml/min/1.73m2. Diagnosis of LN was performed by renal biopsy, and all of the renal biopsies were carried out at urology and nephrology center. The patients will be randomized into two groups Study group: will receive SGLT2i as add on drug or replace another drug according to the patient clinical situation, Dapagliflozin 10 mg will be used once daily with or without food. Control group: will be maintained on their medication. Study Protocol: Patients in the study group will treated with dapagliflozin initiated at a total daily dosage of 10 mg once daily. Methods: The following data will be gathered and evaluated for all patients: I-before intervention: Patients of both groups will be subjected to full history taking including duration of LN and drug history and routine clinical examination including blood pressure and BMI measurements. Laboratory investigations: Serum creatinine, Creatinine clearance. 24 hour urine protein, urine protein/creatinine ratio. Urine analysis. HBA1c. hemoglobin (HGB). Uric acid and lipid profile. Lupus serology. immunoreactive parathyroid hormone (iPTH). Vitamin D level. Fibroblast growth factor 23 level. bone turnover markers : bone specific alkaline phosphates propeptides of type 1 procollagen tartrate resistant acid phosphatase 5b sclerostin level Radiological investigation: Quantitative computed tomography: to detect bone and mineral density (BMD). Cardiovascular assessment: Echocardiography and vascular calcification incidence (NCCT model) : for detection of coronary calcification. II-after intervention: All patients will be evaluated monthly regarding: Regular measurement of blood pressure each visit. Laboratory investigations: Serum creatinine, creatinine clearance. 24 hour proteinuria, protein/creatinine ratio. Fasting, random and postprandial glucose levels. calcineurin inhibitors (CNI) trough level if used. Urine analysis. HGB level. Uric acid, lipid profile. Lupus serology. All patients will be evaluated every 3 month regarding: 1. iPTH 2. Vitamin D level All patients will be evaluated at 12 month regarding: 1. Fibroblast growth factor 23 level 2. High resolution quantitative computed tomography. 3. Bone turnover markers.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 100
Est. completion date December 8, 2023
Est. primary completion date October 8, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age of patient is more than 18. - Patients who are willing to sign informed consent. - Patients with SLE diagnosed according to EULAR/ACR classification criteria. - Patients with LN according to renal biopsy. - Patients with eGFR > 30 ml/min/1.73m2. Exclusion Criteria: - With eGFR <30 ml/min per 1.73 m2. - Who is currently pregnancy or lactation. - With medical history of chronic disease (chronic liver disease, cancer, severe respiratory distress, gastrointestinal tract lesions). - Refuse to participate in the study or lost follow up. - With evidence of urinary obstruction of difficulty in voiding at screening. - Who are receiving high dose diuretics or combined angiotensin-converting enzyme inhibitor (ACEI) and Angiotensin II receptor blockers (ARBS). - Who have frequent hypotensive episode or systolic blood pressure <100 mmHg. Active malignancy. - Active infection including HIV. - Any medications that may affect or interact with bone metabolism such as calcitonin, , denosumab, estrogen and fluoride during the last 6 months. - Current or previous organ transplantation, or expected to get a kidney transplant within 12 months

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Dapagliflozin tablet
randomized control trial, study group will receive dapagliflozin tablets
placebo
randomized control trial, control group will receive placebo tablets

Locations

Country Name City State
Egypt Urology and Nephrology Center Mansoura

Sponsors (1)

Lead Sponsor Collaborator
Mansoura University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary effect of dapagliflozin on renal function Effect of dapagliflozin on eGFR (ml/ min). 1 year
Primary effect of dapagliflozin on kidney function Effect of dapagliflozin on s.creatinine (mg/dl). 1 year
Primary effect of dapagliflozin on BMD Effect of dapagliflozin on osteoporosis using Qct 1 year
Primary effect of dapagliflozin on minerals Effect of dapagliflozin on serum calcium and phosphorus (mg/dl) 1 year
Primary effect of dapagliflozin on Bone Effect of dapagliflozin on bone turnover markers (ng/dl) 1 year
Secondary effect of dapagliflozin on blood pressure measuring systolic and diastolic blood pressure mmgh before and after intervention 1 year
Secondary effect of dapagliflozin on body weight assessing body weight in kg before and after intervention 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT02936375 - The Iguratimod Effect on Lupus Nephritis (IGeLU) Phase 2
Completed NCT03597464 - Aurinia Renal Assessments 2: Aurinia Renal Response in Lupus With Voclosporin Phase 3
Recruiting NCT01226147 - Efficacy and Safety of Tamibarotene(AM80) for Lupus Nephritis Phase 2
Completed NCT01206569 - Long-Acting Tacrolimus for the Treatment of Resistant Lupus Nephritis Phase 4
Active, not recruiting NCT00569101 - A Pilot Study for the Efficacy and Safety of Tacrolimus in the Treatment of Refractory Lupus Nephritis Phase 2
Terminated NCT00368264 - TNF Blockade With Remicade in Active Lupus Nephritis WHO Class V (TRIAL ) Phase 2/Phase 3
Completed NCT00298506 - Study to Assess the Efficacy and Safety of FK506 Combined With Mycophenolate Mofetil (MMF) in Lupus Nephritis (III/IV/V) N/A
Completed NCT00371319 - Comparing the Efficacy of Tacrolimus and Mycophenolate Mofetil for the Initial Therapy of Active Lupus Nephritis Phase 4
Completed NCT00094380 - Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077) Phase 1/Phase 2
Terminated NCT04376827 - A Study of Guselkumab in Participants With Active Lupus Nephritis Phase 2
Completed NCT03610516 - Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Lupus Nephritis. Phase 2
Recruiting NCT03526042 - Angiotensin-II Receptor Antibodies Blockade With Losartan in Patients With Lupus Nephritis N/A
Withdrawn NCT03859570 - Pentoxifylline in Lupus Nephritis Phase 4
Completed NCT03664908 - Detection of Anti-glomerular Basement Membrane Antibodies (Anti-GBM): a Promising Biomarker for Lupus Nephritis (LN)? N/A
Completed NCT01085097 - A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Nephritis Phase 2
Not yet recruiting NCT06429800 - A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Lupus Nephritis Phase 1
Recruiting NCT02226341 - ACTHar in the Treatment of Lupus Nephritis Phase 4
Recruiting NCT02453997 - Mycophenolic Acid Pharmacokinetics and Pharmacogenomics in Lupus Nephritis N/A
Completed NCT01470183 - Lupus Nephritis Biomarker Study: Baseline Characteristics of Patients N/A
Terminated NCT00089804 - Study of LJP 394 in Lupus Patients With History of Renal Disease Phase 3